"Ticlopidine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
| Descriptor ID |
D013988
|
| MeSH Number(s) |
D02.886.778.823.500 D03.383.725.849.500 D03.383.903.830.500 D03.633.100.928.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Ticlopidine".
Below are MeSH descriptors whose meaning is more specific than "Ticlopidine".
This graph shows the total number of publications written about "Ticlopidine" by people in this website by year, and whether "Ticlopidine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 2 | 0 | 2 |
| 2006 | 2 | 0 | 2 |
| 2007 | 1 | 1 | 2 |
| 2008 | 1 | 1 | 2 |
| 2009 | 4 | 2 | 6 |
| 2010 | 3 | 3 | 6 |
| 2011 | 0 | 2 | 2 |
| 2012 | 2 | 1 | 3 |
| 2013 | 4 | 0 | 4 |
| 2014 | 1 | 0 | 1 |
| 2015 | 0 | 2 | 2 |
| 2016 | 4 | 0 | 4 |
| 2017 | 46 | 28 | 74 |
| 2018 | 4 | 12 | 16 |
| 2019 | 0 | 5 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Ticlopidine" by people in Profiles.
-
Enhanced platelet inhibition by clopidogrel and risk of bleeding in patients requiring oral anticoagulation after drug-eluting stent implantation. EuroIntervention. 2019 Oct 20; 15(8):700-706.
-
Ticagrelor or Prasugrel in Acute Coronary Syndromes - The Winner Takes It All? N Engl J Med. 2019 10 17; 381(16):1582-1585.
-
[Status quo and countermeasure of clopidogrel resistance predicted by gene testing]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2019 Jun 10; 36(6):649-653.
-
Recurrent retinal vein thrombosis: prevention with Aspirin, Pycnogenol®, ticlopidine, or sulodexide. Minerva Cardioangiol. 2019 Apr; 67(2):109-114.
-
Perioperative Management of Antiplatelet Therapy in Patients With History of Coronary Artery Disease Undergoing Surgery for Esophageal Cancer: A Single-center Experience. In Vivo. 2019 Mar-Apr; 33(2):621-626.
-
The Conundrum Surrounding Racial Differences on Ischaemic and Bleeding Risk with Dual Anti-Platelet Therapy. Thromb Haemost. 2019 01; 119(1):9-13.
-
Aspirin-still the GLOBAL LEADER in antiplatelet therapy. Lancet. 2018 09 15; 392(10151):896-897.
-
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet. 2018 09 15; 392(10151):940-949.
-
Effect of Physical Exercise on Platelet Reactivity in Patients with Dual Antiplatelet Therapy. Int J Sports Med. 2018 Jul; 39(8):646-652.
-
Prevention of recurrent venous thrombosis and post-thrombotic syndrome. Minerva Cardioangiol. 2018 Jun; 66(3):238-245.